Akers Biosciences Share Discussion Threads

[algernon2] 17/11/2016 11:11

"Akers Biosciences flags up fundraising plans"

From Proactive Investors:

"In a pre-emptory prospectus filed in the States, it has given itself the flexibility to issue common stock, preferred stock, warrants and/or units.
Akers Biosciences flags up fundraising plans
The company will use the money to grow the business.
Akers Biosciences Inc (LON:AKR, NASDAQ:AKER), the UK and US listed rapid breath test specialist, has flagged up plans to raise up to US$7mln.

In a pre-emptory prospectus filed in the States, it has given itself the flexibility to issue common stock, preferred stock, warrants and/or units.

It says the proceeds will be put to work to grow the company, including bringing new products to the market.

“We have not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes,” the document said.

“Accordingly, our management will have significant discretion and flexibility in applying the net proceeds from this offering.”"

[norbus] 17/11/2016 10:52

This is NOT a successful company; I see the writing on the wall; what hope that I saw there was, sat on M&A. That did not happen. AKR will not trade out to profits and remains a pension for Raymond I see no dramatic uptick in product sales or innovation

If a duck limps as it waddles,then that duck is a lame duck

[algernon2] 16/11/2016 18:42

Down 23% on Nasdaq as I write this.
Cor-Blimey Raymond!!!!

[rivaldo] 16/11/2016 09:24

Cheers re the Proactive interview. Gormally comes across extremely well.

Certainly lots to look forward to. And more optimism about the $2m Chinese sale coming through this quarter, which will be great news if so - they had better deliver it given the apparent confidence.

[mcmather] 16/11/2016 08:43

Aye, but the next placing will still be near 50% down on the nasdaq ipo from Jan 2014.

AYM nearly quadrupled in 48 hours t'other day.

[wigwammer] 16/11/2016 08:11

So true.In the meantime the shares have doubled over the last year.

[norbus] 16/11/2016 07:34

A bird on the tree is worth 2000 on the next tree

[mcmather] 15/11/2016 23:02

Telephone interview; you'll need to copy, paste and join the two bits below:

hxxp://www.proactive investors.co.uk/companies/stocktube/6389/akers-to-launch-products-of-the-future-in-2017-6389.html

Points of possible interest;

The PIFA PF4 test sells at $125 and which would equate to unit sales in the US for the last quarter of just over 4000.

Walt reckons there are 4 million heparin tests in the US each year and a further 4 million in the ROW.

Products scheduled to hit the market next / in 2017:
Keto-Check.
Chlamydia.
Breath PH (2 minute Asthma diagnosis).

[mcmather] 15/11/2016 21:32

Gormally has got a grip; and he needed to because Walt was wayward - today's closing nasdaq share price is about 45% below the IPO.

[wigwammer] 15/11/2016 13:58

Belting.In the meantime the shares have doubled over the last year.

[mcmather] 15/11/2016 13:04

Good word Norbus; belting line that:

...however, the remaining products will be scheduled to ship at various points throughout the remainder of the current fiscal year with the remaining $2,000,000 of revenue under the order being recognized when the criteria for the recognition of revenue is met..

[norbus] 15/11/2016 12:55

Not anywhere near an exit from the wood. Obfuscation about expectations now with half Q4 gone not healthy

[rivaldo] 15/11/2016 12:12

No callers eh - that's what you call "under the radar" :o))

They definitively say that Q4 "is expected to be profitable", and that the rest of the $2.5m Chinese order will be received this quarter. So these things had better happen.

I suspect when/if they announce the receipt of the Chinese cash the share price may go a fair bit higher.

Here's a link to the conference call for the record:

[mcmather] 14/11/2016 14:20

Crikey, no callers on the earnings conference call...

[algernon2] 14/11/2016 11:12

"Akers Biosciences delivers robust growth in third quarter" (From Proactive Investors)

Total revenues grew by 262% to US$613,198 in the three months to September 31
Akers Biosciences delivers robust growth in third quarter
Dual listed Akers develops tech for the healthcare sector
Akers Biosciences PLC (LON:AKR, NASDAQ:AKER) is primed for a strong end to the year after delivering a robust showing in the third quarter.

Total revenues grew by 262% to US$613,198 in the three months to September 31, driven by sales of the company’s flagship PIFA Heparin-PF4 Rapid Assay.

The product is a breath test that is able determine quickly and efficiently whether a person has an allergy to a regularly prescribed blood thinner.

There are a couple of things note in the update. The first is the 341% rise in sales of the units, which raked in US$514,839. The second is these sales came entirely from the US.

Why is that significant? Well, the company didn’t benefit at all from a Chinese order worth US$2.5mln.

The remaining US$2mln of the deal struck with Novotek for PIFA products is expected to go through in the final three months of the year.

Looking at the remainder of the results, Akers’ gross margin improved to 61%, meaning the company booked a gross profit of US$376,498. The company had cash in the bank of US$795,802.

Share

[mcmather] 10/11/2016 23:40

They all seem like "winners" but none have come anywhere near achieving 'gold'.

The Metron device should be able to generate sales now; there was a tri-athlete in the US who tried and endorsed it in 2014 (I think) and which generated lots of enquiries re the device / how easy it was to use / etc.

Unfortunately, but as per everything else, you'll need to ask Dr Walt what happened to matters thereafter.

It'll be very interesting to learn what each of the milestones are that the bell needs to attain to get his $200k salary increase. For a small cap company that produces what revenue again??

[rivaldo] 10/11/2016 13:39

Here's today's RNS re the patent grant:



Agreed re getting Metron sales out there, but the breath test for diabetics seems like a potentially huge winner imho, backed up by the comment in the RNS:

"The technology has a large number of potential mass-market applications, including within health and wellness, but in particular, we believe the ability to help Type 1 and some Type 2 diabetics monitor their ketone levels in a non-invasive, convenient format will be a significant advancement in the management of a disease that affects hundreds of millions of people worldwide," added Dr. Akers."

[mcmather] 10/11/2016 08:19

Need to get selling Metron; the other 2 might well yield numbers in due course but reckon they could start getting Metron units sold in reasonable numbers now and without throwing too much money at it here in Europe with a carefully pitched advertising / pr programme. It's the kind of product / device that will likely be passed on by word of mouth (inc' social media) by like-minded folk.

[mcmather] 09/11/2016 19:45

Q3 results Monday then; is the new fella as big a mitty as walter re what was said last time? Let's see how the PIFA PF4 sales are doing and how many institutes of 200+ hospitals have been signed up.

Not quite sure what this is from 31 Oct 2016; possibly in connection with the Form S3 but?
AKERS BIOSCIENCES INC COM 00973E102 30 9,000 SH DFND 6 0 0 9,000

[mcmather] 07/11/2016 23:17

The Perils Of Value Microcap Research And The Example Of Akers Biosciences.....

[norbus] 04/11/2016 12:54

That's worth a few Remimbis on the P&L

[mcmather] 03/11/2016 10:17

Where's Wally? Waitering by the looks of things.

Akers founder attends high-level China FDA meeting in Beijing on medicine westernization to present PIFA HPF/4

[mcmather] 02/11/2016 23:06

It will obviously be interesting to determine the current position of things; ie are Akers currently trading profitably, as per the (one-off) month of June 2016??

"AKER will report Q3 earnings on 11/11/2016"

From what I have been able to make out the SEC form S3's (ie the $7m 'placing') has a 3 year shelf life / expiration; ie are funds needed immediately / shortly / just in case / etc?

[mcmather] 01/11/2016 14:25

US$3.45 equates to £2.82...